The conference serves as a strategic venue for the German biotechnology company to accelerate the adoption of its diagnostic tools. SphingoTec specializes in out-licensing solutions for acute medical conditions, maintaining a portfolio that features Proenkephalin A 119-159 (penKid) for kidney function assessment and bioactive Adrenomedullin 1-52 (bio-ADM) for monitoring endothelial function in sepsis patients. By engaging with industry leaders at ADLM, the company intends to transition its biomarker innovations into broader clinical use across various IVD platforms.
In section Releases
SphingoTec CEO Deborah Bergmann to Attend ADLM 2026
From July 26 to 30, Hennigsdorf-based diagnostics firm SphingoTec will focus on expanding its clinical reach at the ADLM 2026 Annual Meeting. CEO Deborah Bergmann is set to lead the delegation, aiming to forge new partnerships and advance the commercial integration of the company’s proprietary biomarker portfolio within critical care.
Bergmann emphasized that these interactions are vital for aligning the firm’s technical developments with the practical needs of the diagnostics ecosystem. The company continues to prioritize scaling its commercial presence, utilizing the event to solidify collaborations that support its goal of delivering clinically meaningful diagnostic solutions for critical care environments.
Comments (0)
No comments yet. Be the first!